Literature DB >> 20843808

BRAF drives synovial fibroblast transformation in rheumatoid arthritis.

Richard H Weisbart1, Grace Chan, Emil Heinze, Rachel Mory, Robert N Nishimura, Keith Colburn.   

Abstract

Synovial fibroblasts destroy articular cartilage and bone in rheumatoid arthritis, but the mechanism of fibroblast transformation remains elusive. Because gain-of-function mutations of BRAF can transform fibroblasts, we examined BRAF in rheumatoid synovial fibroblasts. The strong gain-of-function mutation, V600R, of BRAF found in melanomas and other cancers was identified in first passage synovial fibroblasts from two of nine rheumatoid arthritis patients and confirmed by restriction site mapping. BRAF-specific siRNA inhibited proliferation of synovial fibroblasts with V600R mutations. A BRAF aberrant splice variant with an intact kinase domain and partial loss of the N-terminal autoinhibitory domain was identified in fibroblasts from an additional patient, and fibroblast proliferation was inhibited by BRAF-specific siRNA. Our finding is the first to establish mechanisms for fibroblast transformation responsible for destruction of articular cartilage and bone in rheumatoid arthritis and establishes a new target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843808      PMCID: PMC2966042          DOI: 10.1074/jbc.C110.168195

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation.

Authors:  C D Buckley; D Pilling; J M Lord; A N Akbar; D Scheel-Toellner; M Salmon
Journal:  Trends Immunol       Date:  2001-04       Impact factor: 16.687

2.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

Review 3.  Guilty as charged: B-RAF is a human oncogene.

Authors:  Mathew J Garnett; Richard Marais
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

Review 4.  Are fibroblasts involved in joint destruction?

Authors:  T Pap; I Meinecke; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

5.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice.

Authors:  U Müller-Ladner; J Kriegsmann; B N Franklin; S Matsumoto; T Geiler; R E Gay; S Gay
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

6.  Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium.

Authors:  M Inazuka; T Tahira; T Horiuchi; S Harashima; T Sawabe; M Kondo; H Miyahara; K Hayashi
Journal:  Rheumatology (Oxford)       Date:  2000-03       Impact factor: 7.580

7.  B-RAF is a therapeutic target in melanoma.

Authors:  Maria Karasarides; Antonio Chiloeches; Robert Hayward; Dan Niculescu-Duvaz; Ian Scanlon; Frank Friedlos; Lesley Ogilvie; Douglas Hedley; Jan Martin; Christopher J Marshall; Caroline J Springer; Richard Marais
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

8.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

9.  p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis.

Authors:  Yuji Yamanishi; David L Boyle; Douglas R Green; Edward C Keystone; Alison Connor; Susan Zollman; Gary S Firestein
Journal:  Arthritis Res Ther       Date:  2004-10-29       Impact factor: 5.156

10.  B-Raf specific antibody responses in melanoma patients.

Authors:  Joachim Fensterle; Jürgen C Becker; Tamara Potapenko; Veronika Heimbach; Claudia S Vetter; Eva B Bröcker; Ulf R Rapp
Journal:  BMC Cancer       Date:  2004-09-12       Impact factor: 4.430

View more
  3 in total

Review 1.  Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors.

Authors:  Nunzio Bottini; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 2.  Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.

Authors:  Gyrid Nygaard; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2020-05-11       Impact factor: 20.543

Review 3.  Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe.

Authors:  Mohammad Javad Mousavi; Jafar Karami; Saeed Aslani; Mohammad Naghi Tahmasebi; Arash Sharafat Vaziri; Ahmadreza Jamshidi; Elham Farhadi; Mahdi Mahmoudi
Journal:  Auto Immun Highlights       Date:  2021-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.